vorinostat has been researched along with Invasiveness, Neoplasm in 18 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rhein has antitumor and SGK1 suppression effects, although its biological activity is limited by poor bioavailability." | 5.56 | Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. ( Chen, J; Luo, B; Pi, R; Wen, S, 2020) |
| "Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate, Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144)." | 3.83 | Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. ( Andrade, R; Aréchaga, J; Arluzea, J; De Wever, O; Díaz-Núñez, M; Díez-Torre, A; Silió, M, 2016) |
| "Rhein has antitumor and SGK1 suppression effects, although its biological activity is limited by poor bioavailability." | 1.56 | Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. ( Chen, J; Luo, B; Pi, R; Wen, S, 2020) |
| "Vorinostat has good therapeutic efficacy against primary cutaneous T-cell lymphoma in the refractory stage." | 1.56 | Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells. ( Cai, Y; He, Z; Liang, S; Xia, C, 2020) |
| "However, the role of Rnd1 in hepatocellular carcinoma (HCC) progression remains unclear." | 1.48 | The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. ( Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD, 2018) |
| "Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor." | 1.43 | Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. ( Chen, X; Deng, Q; Feng, J; Guo, C; Huang, H; Ma, S; Shen, B; Wu, K; Wu, Z; Xia, B; Zhang, J; Zhang, K; Zhang, S; Zhu, L, 2016) |
| "LW479 could be a candidate drug for breast cancer prevention." | 1.42 | Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression. ( Chen, Y; Dai, F; Gao, D; He, Y; Li, J; Liu, M; Yang, F; Yi, Z; Zhang, T, 2015) |
| "Triple-negative breast cancer (TNBC), defined by the absence of an estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, is associated with an early recurrence of disease and poor outcome." | 1.39 | Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. ( Chen, YA; Chiou, YS; Chiu, HW; Ho, SY; Huang, WJ; Lin, P; Wang, YC; Wang, YJ; Yeh, YL, 2013) |
| "Re-expression of miR-34a in human pancreatic cancer stem cells (CSCs) and in human pancreatic cancer cell lines upon treatment with 5-Aza-dC and SAHA strongly inhibited the cell proliferation, cell cycle progression, self-renewal, epithelial to mesenchymal transition (EMT) and invasion." | 1.37 | Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. ( Nalls, D; Rodova, M; Shankar, S; Srivastava, RK; Tang, SN, 2011) |
| "High grade gliomas are aggressive cancers that are not well addressed by current chemotherapies, in large measure because these drugs do not curtail the diffuse invasion of glioma cells into brain tissue surrounding the tumor." | 1.36 | Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. ( An, Z; Choy, ML; Gluck, CB; Kaufman, LJ, 2010) |
| "This combined therapeutic effect on esophageal cancer epithelial-mesenchymal transition was associated with upregulation of E-cadherin protein expression." | 1.36 | Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. ( Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N, 2010) |
| "Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC)." | 1.36 | Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. ( Bornmann, W; Cristofanilli, M; Hall, CS; Pal, A; Peng, Z; Pickei, R; Robertson, FM; Woodward, WA; Ye, Z, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 15 (83.33) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, N | 2 |
| Takeda, K | 1 |
| Imai, M | 1 |
| Chen, J | 1 |
| Luo, B | 1 |
| Wen, S | 1 |
| Pi, R | 1 |
| Xia, C | 1 |
| He, Z | 1 |
| Cai, Y | 1 |
| Liang, S | 1 |
| Peela, N | 1 |
| Barrientos, ES | 1 |
| Truong, D | 1 |
| Mouneimne, G | 1 |
| Nikkhah, M | 1 |
| Qin, CD | 1 |
| Ma, DN | 1 |
| Zhang, SZ | 1 |
| Zhang, N | 1 |
| Ren, ZG | 1 |
| Zhu, XD | 1 |
| Jia, QA | 1 |
| Chai, ZT | 1 |
| Wang, CH | 1 |
| Sun, HC | 1 |
| Tang, ZY | 1 |
| Chiu, HW | 1 |
| Yeh, YL | 1 |
| Wang, YC | 1 |
| Huang, WJ | 1 |
| Chen, YA | 1 |
| Chiou, YS | 1 |
| Ho, SY | 1 |
| Lin, P | 1 |
| Wang, YJ | 1 |
| Li, J | 1 |
| Zhang, T | 1 |
| Yang, F | 1 |
| He, Y | 1 |
| Dai, F | 1 |
| Gao, D | 1 |
| Chen, Y | 1 |
| Liu, M | 1 |
| Yi, Z | 1 |
| Mahal, K | 1 |
| Kahlen, P | 1 |
| Biersack, B | 1 |
| Schobert, R | 1 |
| Meng, Z | 1 |
| Jia, LF | 1 |
| Gan, YH | 1 |
| Lu, H | 1 |
| Yang, XF | 1 |
| Tian, XQ | 1 |
| Tang, SL | 1 |
| Li, LQ | 1 |
| Zhao, S | 1 |
| Zheng, HC | 1 |
| Díaz-Núñez, M | 1 |
| Díez-Torre, A | 1 |
| De Wever, O | 1 |
| Andrade, R | 1 |
| Arluzea, J | 1 |
| Silió, M | 1 |
| Aréchaga, J | 1 |
| Zhang, S | 1 |
| Wu, K | 1 |
| Feng, J | 1 |
| Wu, Z | 1 |
| Deng, Q | 1 |
| Guo, C | 1 |
| Xia, B | 1 |
| Zhang, J | 1 |
| Huang, H | 1 |
| Zhu, L | 1 |
| Zhang, K | 1 |
| Shen, B | 1 |
| Chen, X | 1 |
| Ma, S | 1 |
| Abe, F | 1 |
| Kitadate, A | 1 |
| Ikeda, S | 1 |
| Yamashita, J | 1 |
| Nakanishi, H | 1 |
| Asaka, C | 1 |
| Teshima, K | 1 |
| Miyagaki, T | 1 |
| Sugaya, M | 1 |
| Tagawa, H | 1 |
| An, Z | 1 |
| Gluck, CB | 1 |
| Choy, ML | 1 |
| Kaufman, LJ | 1 |
| Taylor, MD | 1 |
| Liu, Y | 1 |
| Nagji, AS | 1 |
| Theodosakis, N | 1 |
| Jones, DR | 1 |
| Robertson, FM | 1 |
| Woodward, WA | 1 |
| Pickei, R | 1 |
| Ye, Z | 1 |
| Bornmann, W | 1 |
| Pal, A | 1 |
| Peng, Z | 1 |
| Hall, CS | 1 |
| Cristofanilli, M | 1 |
| Nalls, D | 1 |
| Tang, SN | 1 |
| Rodova, M | 1 |
| Srivastava, RK | 1 |
| Shankar, S | 1 |
| Takada, Y | 1 |
| Gillenwater, A | 1 |
| Ichikawa, H | 1 |
| Aggarwal, BB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Closed by Sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 other studies available for vorinostat and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
Topics: Aminophenols; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibrosarcoma; | 2013 |
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug.
Topics: Anthraquinones; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Movement; Cel | 2020 |
Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fem | 2020 |
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion; | 2017 |
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genet | 2018 |
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell | 2015 |
4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proli | 2015 |
PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
Topics: Acetylation; Animals; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Enzyme Act | 2016 |
The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Topics: Antineoplastic Agents; Apoptosis; Butyrates; Cadherins; Cell Line, Tumor; Gene Expression Regulation | 2016 |
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cel | 2016 |
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation, | 2017 |
Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture.
Topics: 3T3 Cells; Animals; Brain Neoplasms; Cell Adhesion; Cell Movement; Glioma; Humans; Hydroxamic Acids; | 2010 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezo | 2010 |
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.
Topics: Antineoplastic Agents; Breast Neoplasms; Cadherins; Cell Aggregation; Cell Division; Cell Line, Tumo | 2010 |
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatin; | 2011 |
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogens; Carrier Proteins; Cell Differentiation; Cell | 2006 |